Gilead Sciences, Inc. $GILD Stock Sold by Clark Estates Inc. NY

Clark Estates Inc. NY reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 21.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,375 shares of the biopharmaceutical company’s stock after selling 5,647 shares during the period. Gilead Sciences accounts for approximately 0.7% of Clark Estates Inc. NY’s investment portfolio, making the stock its 28th biggest position. Clark Estates Inc. NY’s holdings in Gilead Sciences were worth $3,037,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Global Retirement Partners LLC raised its position in shares of Gilead Sciences by 4.8% in the third quarter. Global Retirement Partners LLC now owns 36,269 shares of the biopharmaceutical company’s stock valued at $5,406,000 after purchasing an additional 1,665 shares during the period. BCGM Wealth Management LLC boosted its holdings in shares of Gilead Sciences by 10.0% during the third quarter. BCGM Wealth Management LLC now owns 15,950 shares of the biopharmaceutical company’s stock worth $2,377,000 after acquiring an additional 1,447 shares during the period. Rothschild Investment LLC grew its holdings in Gilead Sciences by 17.8% in the 3rd quarter. Rothschild Investment LLC now owns 6,190 shares of the biopharmaceutical company’s stock valued at $923,000 after buying an additional 935 shares in the last quarter. Ironwood Investment Counsel LLC grew its stake in shares of Gilead Sciences by 12.5% in the third quarter. Ironwood Investment Counsel LLC now owns 3,567 shares of the biopharmaceutical company’s stock valued at $532,000 after acquiring an additional 396 shares in the last quarter. Finally, Edgestream Partners L.P. acquired a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $2,745,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Morgan Stanley raised their price objective on Gilead Sciences from $163.00 to $183.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Bank of America lifted their target price on Gilead Sciences from $168.00 to $172.00 and gave the company a “buy” rating in a research report on Tuesday, October 20th. Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $146.00 to $127.00 in a research note on Tuesday, July 21st. Finally, Barclays boosted their target price on Gilead Sciences from $145.00 to $160.00 and gave the stock an “equal weight” rating in a research note on Monday. Twenty-three analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $171.63.

Read Our Latest Stock Analysis on Gilead Sciences

Gilead Sciences News Roundup

Investors following GILD have been watching these news items:

  • Positive Sentiment: Gilead signed royalty-free licenses with three generic manufacturers to support potential future access to investigational Ebola drug obeldesivir in 127 countries. The initiative expands access if the drug is authorized, but is unlikely to generate meaningful near-term sales while it remains experimental. Reuters: Gilead signs generic licensing deals for experimental Ebola drug
  • Neutral Sentiment: Gilead completed a new Foster City research center, adding specialized laboratory capacity. This may support research over time, but the completion itself does not indicate a near-term financial impact. Research center completion
  • Negative Sentiment: Barclays maintained an equal-weight/hold stance while raising its price target to $160, still below the $170.26 price cited in the stock-performance information. That gap highlights valuation risk after GILD’s strong run. Barclays rating

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $170.26 on Wednesday. The company’s 50 day moving average price is $155.90 and its two-hundred day moving average price is $142.09. The firm has a market capitalization of $211.18 billion, a P/E ratio of -53.88 and a beta of 0.35. Gilead Sciences, Inc. has a fifty-two week low of $116.88 and a fifty-two week high of $176.58. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The company had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. During the same period in the prior year, the business earned $2.47 earnings per share. The company’s revenue for the quarter was up 6.8% compared to the same quarter last year. On average, equities analysts forecast that Gilead Sciences, Inc. will post -0.97 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 1.9%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s payout ratio is -103.80%.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel O’Day sold 9,810 shares of the company’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $175.17, for a total value of $1,718,417.70. Following the completion of the transaction, the chief executive officer owned 551,683 shares of the company’s stock, valued at $96,638,311.11. This represents a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $171.47, for a total transaction of $514,410.00. Following the completion of the transaction, the chief financial officer owned 158,096 shares of the company’s stock, valued at approximately $27,108,721.12. This trade represents a 1.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 242,709 shares of company stock valued at $40,524,237. 0.30% of the stock is currently owned by company insiders.

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Featured Articles

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.